Dosimetric analyses of intra-arterial versus standard intravenous administration of 177Lu-DOTATATE in patients of well differentiated neuroendocrine tumor with liver-dominant metastatic disease
| Autor: | Ishita Sen, Virupakshappa Cb, Parul Thakral, Subha Shankar Das, Divya Manda, Dharmender Malik |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Pilot Projects Disease Neuroendocrine tumors Octreotide Gastroenterology Coordination Complexes Internal medicine Organometallic Compounds 177Lu-DOTATATE Intra arterial Humans Medicine Radiology Nuclear Medicine and imaging In patient Prospective Studies Aged Full Paper business.industry Liver Neoplasms Radiotherapy Dosage General Medicine Middle Aged medicine.disease Well differentiated Neuroendocrine Tumors Injections Intra-Arterial Administration Intravenous Female Neoplasm Grading Radiopharmaceuticals business |
| Zdroj: | Br J Radiol |
| ISSN: | 1748-880X 0007-1285 |
| Popis: | Objective: The aim of the present study was to perform calculation of the absorbed doses to organs at risk and to neuroendocrine tumors and to determine whether hepatic intra-arterial (IA) injection of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) would achieve higher intratumoral concentrations than standard intravenous administration of 177Lu-DOTATATE. Methods: 29 patients with Grade I-II, inoperable, metastatic gastro-entero-pancreatic neuroendocrine tumor (GEPNET) were prospectively identified and enrolled for the study. 15 patients of GEPNETs with liver-dominant metastatic disease and less than 3 sites of extrahepatic metastatic disease were administered a single dose of 177Lu-DOTATATE therapy through the selective catheterization of the hepatic artery (IA group). The other 14 patients received a single dose of 177 Lu- DOTATATE through standard intravenous route (IV group). For dosimetry, whole-body γ (anterior and posterior planar acquisitions) and SPECT/CT scans of the abdomen at 2, 24 and 96 h post 177Lu-DOTATATE administration were acquired. Dosimetric calculations were done using the HERMES software. Results: The mean dose per unit activity (DpA) in the liver and tumor lesions in the IA group differed significantly (p < 0.05) but differed insignificantly in spleen and kidneys (p > 05) with the IV group. The mean tumor/non-tumor concentration at 96 h was 76.83 ± 7.9 (range 10.2–251.3) in the IA group whereas it was 25.6 ± 5.9 (Range: 12–55) in the IV group. There was an average threefold increase in tumoral concentration over the standard intravenous group. Conclusion: IA administration of 177Lu-DOTATATE results in higher concentration and absorbed dose in hepatic metastases in patients of GEPNETs as compared to a single dose of PRRT administered through standard IV route, and thus seems to be a powerful tool to improve the efficacy of PRRT. Advances in knowledge: Measurement of the dose received by the tumor lesions and the critical organs is of paramount importance for the prognostication of a radionuclide therapy. Scant data exist on the dosimetric impact of IA administration of the therapy with 177Lu-DOTATATE on the tumors and other organs, and this study would add an impact towards the better treatment outcome in patients of neuroendocrine tumor with liver-dominant metastatic disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|